Jazz Hopes Pediatric Vaccinations Can Speed Epidiolex Uptake

The pandemic has dampened the seizure drug’s sales, but the company is hoping to see a pickup as an expanding patient base could help it achieve anticipated blockbuster sales.

Epilepsy brain — Jazz reported lower-than-expected sales growth for Epidiolex, but it expects to see a pickup • Source: Shutterstock

Jazz Pharmaceuticals plc is still feeling the weight of the pandemic on its epilepsy drug Epidiolex (cannabidiol), but it anticipates that COVID-19 vaccinations for young children will give a boost to sales of the cannabis-based drug, which the company sees as having “blockbuster potential.”

Jazz said 9 November that overall revenues for the company saw a significant gain in the third quarter from the comparable period of 2020, rising 39% to $838.1m, in line with consensus estimates. But while sales of Epidiolex saw a 21% increase to $160.4m, that came in below analyst forecasts that ranged from $164m-$173m. The company raised its full-year earnings guidance from a range of $830m-$910m to $925m-$965m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

08 May 2025

• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.